Inactief instrument

Andere talen InMed Pharmaceuticals Inc Canadian Securities Exchange

Aandelen

IN

CA4576371062

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board	18/04
InMed Pharmaceuticals Inc. Appoints David G. Morgan to its Scientific Advisory Board	18/04
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration	16/04
InMed Pharmaceuticals Inc. Announces Additional Preclinical Data Demonstrating INM-901'S Positive Pharmacological Effects in the Potential Treatment of Alzheimer's Disease	04/04
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies	04/04
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance	20/03
InMed Pharmaceuticals Inc. Provides Update on Pharmaceutical Development Programs	13/02
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update	13/02
InMed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	13/02
InMed Pharmaceuticals Inc. Announces Chief Financial Officer Changes, Effective February 20, 2024	09/02
InMed Pharmaceuticals Inc. Announces Executive Changes, Effective February 20, 2024	09/02
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer	09/02
InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET	18/01
InMed Pharmaceuticals Provides Business Update and Milestones for 2024	16/01
InMed Announces Results of 2023 Annual General Meeting	20/12
Inmed Pharmaceuticals Inc. Announces the Launch of Inm-089	29/11
InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration	29/11
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update	14/11
InMed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	14/11
InMed Pharmaceuticals Inc. Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch 2023	02/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen InMed Pharmaceuticals Inc Canadian Securities Exchange

Aandelen

IN

CA4576371062

Andere talen

Filters